Failure of a cytoprotective dose of arbaprostil to heal acute duodenal ulcers. Results of a multiclinic trial.

Abstract

Previous therapeutic trials with prostaglandins have shown them to be effective in healing duodenal ulcers when used at doses that are highly effective suppressors of gastric acid secretion. We undertook this trial to determine if a cytoprotective dose of arbaprostil (10 micrograms q.i.d. for 4 wk) would also be efficacious in this disease state. Eighty-two patients between the ages of 19 and 72 yr with endoscopically documented duodenal ulcers were entered into this randomized double-blind placebo-controlled trial. The patients were monitored with biweekly endoscopies and laboratory examinations, weekly interviews during the period when drug was administered, and a follow-up interview plus laboratory examinations 1 wk after drug administration was completed. No statistically significant differences between the arbaprostil and placebo treatment groups were found for ulcer healing rates, pain relief, antacid consumption, side effects, or laboratory examinations. It is presumed that this prostaglandin may not have sufficient duodenal cytoprotective capacity to effectively heal duodenal ulcers, or that some suppression of gastric acid secretion may be required to achieve significant clinical efficacy.

• Authors: A R Euler, G Tytgat, J Berenguer, H Brunner, D R Wood, J L Lookabaugh, T D Phan
• Journal: Gastroenterology (Gastroenterology) Vol. 92 Issue 3 Pg. 604-7 (Mar 1987) ISSN: 0016-5085 [Print] United States
• PMID: 3545965 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Prostaglandins E, Synthetic
• Arbaprostil

Topics

• Adult
• Aged
• Arbaprostil (administration & dosage, therapeutic use)
• Clinical Trials as Topic
• Double-Blind Method
• Duodenal Ulcer (drug therapy)
• Female
• Humans
• Male
• Middle Aged
• Prostaglandins E, Synthetic (therapeutic use)
• Random Allocation
• Wound Healing (drug effects)